Advertisement

Transradial access for visceral endovascular interventions in morbidly obese patients: safety and feasibility

Transradial access for visceral endovascular interventions in morbidly obese patients: safety and feasibility

J Vasc Access 2016; 17(3): 256 - 260

Article Type: ORIGINAL ARTICLE

DOI:10.5301/jva.5000530

Authors

Derek M. Biederman, Brett Marinelli, Paul J. O’Connor, Joseph J. Titano, Rahul S. Patel, Edward Kim, Nora E. Tabori, Francis S. Nowakowski, Robert A. Lookstein, Aaron M. Fischman

Abstract

Transradial access (TRA) has been shown to lower morbidity and bleeding complications compared to transfemoral access in percutaneous coronary interventions. Morbid obesity, commonly defined as a body mass index (BMI) ≥40 kg/m2, has been shown to be a risk factor for access site complications irrespective of access site. This study evaluates the safety and feasibility of performing visceral endovascular interventions in morbidly obese patients via TRA.

Procedural details, technical success, and 30-day major and minor access site, bleeding, and neurological adverse events were prospectively recorded in a database of 1057 procedures performed via the radial artery. From this database we identified 22 visceral interventions performed with TRA in 17 morbidly obese patients (age: 53 ± 11 years, female: 71%) with a median BMI of 42.7 kg/m2.

Interventions included radio-embolization (n = 7, 31.8%), chemo-embolization (n = 6, 27.3%), uterine fibroid embolization (n = 4, 18.2%), renal embolization (n = 2, 9.1%), hepatic embolization (n = 1, 4.5%), lumbar artery embolization (n = 1, 4.5%), and renal angioplasty (n = 1, 4.5%). The technical success was 100%. There were no major or minor adverse access site, bleeding, or neurological complications at 30 days.

This study suggests visceral endovascular interventions performed in morbidly obese patients are safe and feasible.

Article History

Disclosures

Financial support: None.
Conflict of interest: R.S. Patel is a consultant at Sirtex Medical Ltd Research, and Arstasis, Inc. E. Kim is a consultant at Koninklijke Philips Electronics NV; on the Advisory Board at Onyx Pharmaceuticals, Inc.; Speaker’s Bureau at BTG International Inc. R.A. Lookstein is a consultant at Bayer AG, Johnson & Johnson, and Boston Scientific Corporation. A.M. Fischman is a consultant at Surefire Medical, Inc. and Terumo Corporation. All other authors have nothing to disclose.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Biederman, Derek M. [PubMed] [Google Scholar]
  • Marinelli, Brett [PubMed] [Google Scholar]
  • O’Connor, Paul J. [PubMed] [Google Scholar]
  • Titano, Joseph J. [PubMed] [Google Scholar]
  • Patel, Rahul S. [PubMed] [Google Scholar]
  • Kim, Edward [PubMed] [Google Scholar]
  • Tabori, Nora E. [PubMed] [Google Scholar]
  • Nowakowski, Francis S. [PubMed] [Google Scholar]
  • Lookstein, Robert A. [PubMed] [Google Scholar]
  • Fischman, Aaron M. [PubMed] [Google Scholar] , * Corresponding Author (aaron.fischman@mountsinai.org)

Affiliations

  • Division of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York - USA

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.